Targeted TG2 therapies in the treatment of celiac disease and liver fibrosis have recently been progressed to Phase 2b clinical trials [22,23]; however, there remains a need to further investigate the roles of TG2 in other biological contexts. Here, TGM2 is linked to celiac disease.